Clinical Translation of Anti-PECAM-1 Monoclonal Antibody as an

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$198,751.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
N43CO201000116
Award Id:
96365
Agency Tracking Number:
N43CO201000116
Solicitation Year:
n/a
Solicitation Topic Code:
NCI
Solicitation Number:
n/a
Small Business Information
GENOMIC SYSTEMS, LLC, 290 LOWELL AVE, PALO ALTO, CA, 94301
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
825061778
Principal Investigator:
ROBERTDEBS
() -
Business Contact:
(650) 906-5631
Research Institute:
n/a
Abstract

Most patients who die from cancer succumb to advanced metastatic cancer. These patients, are mostoften treatment-refractory, and comprise the largest untapped market in cancer. We have developed a uniquely effective anti-PECAM-1 monoclonal antibody (mAb)-based therapy. To our knowledge, this mAb is the only treatment that safely and effectively treats advanced tumor metastases, independent of tumor type. Clinical translation of anti-PECAM-1 mAb therapy could revolutionize the treatment of this now-refractory clinical entity. Therefore, we propose to perform the following pre-clinical studies required to translate antiPECAM- 1 mAb-based therapy into phase I clinical trials in cancer patients.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government